CNA FINANCIAL CORP (CNA): what the price requires

At today's price, CNA FINANCIAL CORP (CNA) is priced for 10.1% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/CNA

Headline

FieldValue
TickerCNA
CompanyCNA FINANCIAL CORP
Current price$51.87/sh
CompositionSpecialty 42% / Commercial 48% / Life & Group 10%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed10.1%
Return on equity now11.0%
ROE gap-0.9pp
Price-to-book1.29x

Solve inputs: computed at a 8.7% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~1.3pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+1.37σ
cohort percentile (of 80 peers)31
sustained it ~10 years at this level76%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.98x3justifies
Earnings0.72x2justifies
Relative0.97x3justifies
Growth0.75x2justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.8%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$57.290.91xyesTBVPS $39.33 × 1.46x (ROE (TTM) 11.2% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelative$51.041.02xyesP/E 11x (sector median), scenarios: 9.3x / 11.0x / 12.7x (bear / base = sector held flat / bull), EV/EBITDA 22x
Simple DDMGrowth——no—
Two-Stage DDMGrowth$355.280.15xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$48.241.08xyesBV/sh $39.87, ROE (TTM) 11.2%, ke 9.3%
Two-Stage Excess ReturnAsset$52.860.98xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$38.411.35xyesRev $15.0B, growth 4% (input: historical growth; tapered), Terminal P/S: 0.8x / 0.9x / 1.1x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$53.640.97xyesEPS $4.47, growth 2% (input: historical EPS growth), PEG=5.81 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$63.330.82xyes√(22.5 × EPS $4.47 × BVPS $39.87) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$144.230.36xyesEPS $4.47 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$167.630.31xyesEPS $4.47 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$48.321.07xyesEPS $4.47 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-0.1%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

The clearest read on CNA is how it returns capital, because that is where a well-run insurer signals its confidence. In April the company raised its regular quarterly dividend to $0.48 and paid a $2.00 special dividend, the kind of payout an insurer makes only when it judges its capital comfortably in excess of what the business needs. The special dividend is not a one-off gimmick; it is CNA's established way of distributing the surplus its float and underwriting generate, and it sits on top of a steadily covered regular dividend. For an investor, that combination is a tangible, recurring return while the rest of the thesis plays out.

The underlying franchise is a solid, well-capitalized commercial insurer earning a respectable return on its capital. CNA has been earning a return on equity around 11% on year-end book, above the roughly 9% the price assumes it can sustain, and the quality of that capital was just affirmed by AM Best upgrading its property-casualty subsidiaries to A+ Superior. Financial-strength ratings matter in commercial insurance because buyers of specialty and commercial coverage care that the insurer will be solvent when a long-tail claim finally comes due; an A+ rating is a competitive asset that helps CNA retain and price business. Net investment income, the income the float earns while CNA holds premiums before paying claims, came in at $610 million, a steady contributor that rises as the bond portfolio reinvests at higher yields.

The valuation is where the bull gets comfort, because the market is pricing CNA below its peers. The stock trades at roughly 1.1 times book value, in the lower half of the peer group's price-to-book, even though it earns a return on equity near the middle of that group. The asset-based, earnings-power, and relative-multiple methods all land above the price, which is the signature of a value-supported name rather than a growth bet. The bull case is a steadily profitable insurer, freshly upgraded, returning capital generously, and trading at a discount to both its peers and its own demonstrated returns.

Bear Case

The sector cycle is turning against the bear's favorite worry, and the first quarter showed it. CNA's property-casualty combined ratio rose to 102.2% from 98.4% a year earlier, which means claims and expenses exceeded premiums in the quarter, so the underwriting itself lost money before investment income. Some of that was catastrophe losses, but the more troubling part was 4.1 points of unfavorable prior-period reserve development, driven by excess casualty and professional liability lines in recent accident years. Reserve strengthening is an insurer admitting that claims it booked in prior years are coming in worse than expected, and casualty social inflation, the trend of larger jury awards and litigation costs, is the force behind it. AIG describes the same accounting that makes this hard to see in advance, the combined ratio adjusted for "prior year development, net of premium adjustments", and prior-year development is exactly where CNA's quarter deteriorated.

That underwriting pressure undercuts the return the valuation depends on. An insurer is worth the return it earns on its capital, and the price assumes CNA sustains a return on equity around 9%. The company has recently earned about 11%, but a combined ratio above 100% and continued reserve strengthening are precisely what would pull that return down toward, or below, the assumed level. If casualty and professional-lines losses keep developing adversely, the underlying earnings power that supports the dividend and the book value erodes, and the discount to peers that looks like value today would simply reflect a business whose returns are fading.

The structural overhang is the ownership and the runoff book. CNA is majority-controlled by Loews, so minority holders have limited say in capital allocation, and the large special dividend partly serves the parent's income needs as much as the minority's. The Life and Group segment is a long-tail runoff book, including long-term care exposure, the kind of liability that has surprised insurers to the downside for years and that ties up capital against uncertain future claims. Because CNA is an insurer, the usual solvency lenses, net debt and coverage, do not apply; what matters is regulatory capital and reserve adequacy, and the bear's case is that the reserves may not be as adequate as the book value implies. The valuation discount is real, but a discount on an insurer with a combined ratio above breakeven and a history of casualty reserve development is the market pricing the risk that the earned return keeps slipping.

Valuation

The right frame for CNA is the one for any insurer: it is worth the return it earns on its capital, read off price-to-book rather than an operating multiple. At today's price the market assumes CNA sustains a return on equity around 9%, paying roughly 1.1 times book value. That assumed return is below the roughly 11% CNA has recently earned, which is the crux: the price is not demanding more than the company has shown, it is conservatively assuming a step down from it. The price-to-book also sits in the lower half of the peer group, so on the metric that matters most for an insurer, CNA is cheap relative to both its own record and its competitors.

The method families confirm the value read, with the insurance lenses doing the work. The price-to-tangible-book model, anchored on tangible book of about $39 a share and CNA's roughly 11% return on equity against its cost of equity, lands well above the price. The asset-based excess-return methods, reading the insurer off its book value and the spread of its return over the cost of capital, land above the price. The relative-multiple method, on a sector earnings multiple near 11 times, also lands above it. The growth-dependent methods are largely uninformative here, because an insurer's value comes from its return on capital, not from revenue growth. When the price-to-book, the excess-return, and the relative methods all say the price is below fair value, the read is a value or asset-supported situation: the market is paying less than the demonstrated economics support.

Solvency for an insurer is about regulatory capital and reserve adequacy, not the corporate leverage lenses, and here the signals are mostly reassuring with one caveat. The recent AM Best upgrade to A+ Superior affirms the capital strength, and the large special dividend confirms management sees excess capital. The capital-return capacity, the regular plus special dividend measured against earnings, is generous and covered by the roughly $0.83 of core income per share the company generated in the quarter. The caveat is reserve development: the quarter's unfavorable prior-period development in casualty and professional lines is the one place where the book value, and therefore the value all these methods rest on, could prove less solid than it looks. The decisive variable is whether the underwriting return stabilizes; if it does, the discount to peers is the opportunity, and if reserves keep developing adversely, the discount is the warning.

Catalysts

The capital-return announcements are the most concrete recent catalyst. CNA raised its regular quarterly dividend to $0.48 and declared a $2.00 special dividend, a 4% increase to the regular payout alongside the special, reflecting strong cash generation and management confidence. For a controlled insurer, the special dividend is the principal way surplus reaches shareholders, so its size and recurrence are the income story to track.

The underwriting trajectory is the catalyst that matters most for the earnings. The first quarter's combined ratio of 102.2%, with 4.1 points of unfavorable prior-period development in excess casualty and professional lines, is the signal to watch. P&C renewal premium change of +3% with written rate up 2% shows CNA is still raising prices, and whether those rate increases outrun the casualty loss-cost inflation is what determines if the combined ratio moves back below 100% in coming quarters. Net investment income of $610 million is a steadier contributor that rises as the portfolio reinvests at higher yields.

The credit and ownership backdrop frames the rest. AM Best upgraded CNA's property-casualty subsidiaries to A+ Superior, a competitive asset in commercial insurance and a vote of confidence in the balance sheet. The Life and Group runoff book, including long-term-care exposure, remains a source of potential reserve surprises to monitor, and Loews's majority ownership shapes capital allocation. The events to watch are the quarterly reserve-development disclosures and whether pricing discipline restores an underwriting profit.

Peer Cohorts (Per Segment, With Filing Citations)

Specialty (reported)

Commercial (reported)

Life & Group (reported)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 dividend announcements and AM Best, 2026 · Q1 2026 dividend announcements · AM Best, 2026 · Q1 2026 results

View the full interactive CNA report on boothcheck